{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-015662","form_type":"8-K","ticker":"MAIA","cik":"0001878313","company_name":"MAIA Biotechnology, Inc.","filed_at":"2026-04-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.225508+00:00","generated_at":"2026-05-15T06:55:47.535147+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"MAIA Biotechnology: $33M raise fully funds pivotal Phase 3 trial for ateganosine in NSCLC","bullets":["Net proceeds from $33M March 2026 common stock offering expected to fully fund pivotal Phase 3 trial (THIO-104) for ateganosine in third-line NSCLC.","FDA granted Fast Track designation for ateganosine, a dual mechanism telomere-targeting agent, for third-line NSCLC treatment.","Statistical assessments based on Phase 2 data point to high probability of technical success in Phase 3 full approval trial.","Interim Phase 3 data expected next year; may support FDA discussion for early full commercial approval in third-line NSCLC."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-015662","json":"https://secwatch.observer/filing/0001493152-26-015662.json","markdown":"https://secwatch.observer/filing/0001493152-26-015662.md","text":"https://secwatch.observer/filing/0001493152-26-015662.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1878313/000149315226015662/0001493152-26-015662-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1878313/000149315226015662/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T06:55:47.535147+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}